+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 79Years
All Genders
ID05314998

Phase III Trial Comparing Chemotherapy Allocation by Transcriptomic Signature Versus Standard Criteria for Resected Pancreatic Ductal Adenocarcinoma

Led by John Neoptolemos · Updated on 2026-08-27

394

Participants Needed

33

Research Sites

74 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating disease-free survival in patients with resected pancreatic ductal adenocarcinoma PDAC through a multicenter, open-label phase III trial. The study compares chemotherapy allocation based on a transcriptomic treatment specific stratification signature TSS with the standard clinical criteria. The main goal is to see if using the TSS to guide treatment choice improves patient outcomes compared to current standard methods. Participants receive adjuvant chemotherapy with either mFOLFIRINOX a combination of 5-FU, folinic acid, irinotecan, and oxaliplatin or GemCap gemcitabine and capecitabine. In the test arm, treatment is assigned according to the individual transcriptomic signature, while in the control arm, treatment follows standard clinical criteria. Chemotherapy cycles last about 24 weeks, with drugs given in specific doses and schedules, including infusions every 14 days for mFOLFIRINOX and cycles of 28 days repeated six times for GemCap. During the study, participants are closely monitored for disease-free survival up to 76 months. Assessments include overall survival, metastasis-free survival, quality of life using the EORTC QLQ-C-30 questionnaire, and safety evaluations of adverse events and toxicities. The study also includes optional translational research with collection of tumor specimens and blood samples to identify biomarkers predicting chemotherapy response or relapse, development of patient-derived organoids, and a longitudinal blood biobank for analyzing circulating biomarkers. The total study duration extends through primary completion in April 2033 and final completion in September 2034.

CONDITIONS

Brief Title

Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

Research Team

J

John Neoptolemos, Prof. Dr.

C

Claudia Pauligk, Dr.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here